Document is current

Article History

Received: 3 April 2025

Accepted: 19 January 2026

First Online: 26 February 2026

Declarations

:

: All animal experiments were conducted in strict compliance with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals (2020 Edition) and the Laboratory Animal Guidelines for Euthanasia from China (standard number: GB/T 397602021). Throughout the study, we adhered to the 3R principles, emphasizing the reduction in the number of animals used, the replacement of animals where possible, and the refinement of experimental conditions and procedures to minimize distress or pain. The number of animals, experimental design, and animal handling were approved by the Institutional Animal Care and Use Committee (IACUC) of Hubei Tianqin Xinshi Biotechnology Co., Ltd. (Approval No.: IACUC-A2022011-T011-01).

: Not applicable. This study did not involve human participants; human peripheral blood mononuclear cells used in this study were obtained from commercial sources.

: Not applicable.

: Data are available upon reasonable request.

: The authors declare that they have no competing interests.

: Conception and design: Huilun Chu, Junping Lv, Haifeng Song. Antibody development: Guili Xu, Niliang Qian, Xin gao. In vivo efficacy study: Huilun Chu, Junping Lv. Pharmacokinetic study: Yunlong Liu, Lun Ou, Huilun Chu. In vitro study: Yujie Liu, Xiujie Pan, Guili Xu, Huilun Chu. Toxicity Study: Yanchuan Li, Huilun Chu. Analysis and interpretation of data: all authors. Writing of the manuscript: Huilun Chu, Guili Xu, Xin gao. All authors have read and approved the final version of the manuscript and consent to its publication.

: Not applicable.

: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. For inquiries regarding data and materials, please contact Huilun Chu at Guangxi Ardeon Therapeutics Co., Ltd. (email: chuhl@ardeontx.com).